These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32247750)

  • 1. Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.
    Ramya K; Suresh R; Kumar HY; Kumar BRP; Murthy NBS
    Bioorg Med Chem; 2020 May; 28(10):115466. PubMed ID: 32247750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
    Powers B; Greene L; Balfe LM
    J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system blocking drugs.
    Robles NR; Cerezo I; Hernandez-Gallego R
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.
    Volpe M; Pontremoli R; Borghi C
    High Blood Press Cardiovasc Prev; 2011 Sep; 18(3):93-105. PubMed ID: 21950781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
    Scott BB; McGeehan GM; Harrison RK
    Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin inhibition: a new modality for hypertension management.
    Siragy HM
    Curr Hypertens Rep; 2007 Aug; 9(4):291-4. PubMed ID: 17686379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development.
    Jadhav M; Yeola C; Zope G; Nabar A
    J Postgrad Med; 2012; 58(1):32-8. PubMed ID: 22387646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
    Buczko W; Hermanowicz JM
    Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
    Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
    Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
    Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
    Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
    Gullapalli N; Bloch MJ; Basile J
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.